SDGR · Schrodinger, Inc.
$27.20
-1.70 (-5.88%)
At close · Oct 7
Return incl. dividend (before tax)
Market Cap
$2.16B
Shares
74.81M
Volume · Oct 7
4.56M
Avg daily vol (3M)
1.68M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.90
Open$32.99
Day$28.56–33.78
52W close$11.07–32.60
Avg vol 30d2.4M
Short int11.2M · 14.9% float · 8.7d
Short vol41%
Last earningsAug 5, 2026
DataFeb 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+35.7%
Trailing year
Short interest
14.9%
Latest settlement · 8.7 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Schrödinger delivered 27% Q2 ACV growth to $29.6M, launched its Bunsen AI co-scientist with a new BMS agreement, raised full-year drug discovery revenue guidance to $65-75M on a $10M Ajax milestone, and swung to a $6M GAAP net income from a $43M loss, while reaffirmed ACV guidance of $218-228M continues to imply 10-15% growth.
Bullish
- + Q2 ACV grew 27% to $29.6M, with ex-contribution ACV up 23% at the upper end of expectations
- + Drug discovery revenue jumped to $23M from $13.9M on a $10M Ajax milestone and full-year guidance raised to $65-75M from $55-65M
- + Q2 swung to $6M GAAP net income from a $43M loss, aided by a $48.9M gain from Lilly's acquisition of Ajax
- + Launched Bunsen AI co-scientist in early access and signed a strategic software agreement with Bristol-Myers Squibb expanding platform deployment
Bearish
- − Software revenue declined 10% to $32.5M and software gross margin compressed to 71% from 76% due to the planned accelerated hosted transition
- − Contribution revenue fell to $3.4M from $4.8M as initial Gates Foundation predictive toxicology funding was completed
- − Full-year ACV guidance of $218-228M was reiterated, implying just 10-15% growth and a continued drag from hosted mix shift
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+80%
above
Price vs 50-day avg
+32%
above
RSI (14)
58
neutral
MACD trend
Negative
52-week position
83%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+44%
trailing
6-month return
+133%
trailing
YTD return
+62%
this year
Relative strength
+122%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $22 › 200d $16 — 50d above 200d
Institutional flow
Distributing
2 of 233 funds reported for Sep 30 · net -701 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.93% of float · ▲ +0.7% MoM · 8.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
233 holders — mid 3-yr range
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+23%
Y/Y
Gross margin
56%
contracting
EPS growth
+45%
Y/Y
Free cash flow
$12.5M
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
ACV
· fiscal year ending December 31, 2026
Initiated
$218M – $228M
Drug discovery revenue
· fiscal year ending December 31, 2026
Initiated
$65M – $75M
Prior guidance
period ended
· from the 8-K filed Aug 5, 2026
ACV excluding contribution ACV
· third quarter of 2026
$41M – $45M
Guided vs delivered
· last 2 settled
Total revenue
fiscal year ending December 31, 2022
guided $167M – $175M
$180.96M
Beat +5.8%
Total revenue
full-year 2021
guided $124M – $134M
$137.93M
Beat +6.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+80%
Bullish
Price vs 50-day avg
+32%
Bullish
RSI (14)
58
Neutral
MACD trend
Negative
Bearish
52-week position
83%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $22 › 200d $16 — 50d above 200d
Institutional flow
Distributing
2 of 233 funds reported for Sep 30 · net -701 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.93% of float · ▲ +0.7% MoM · 8.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
233 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $11
Now $29 · 83%
Range high $33
vs 200-day avg +80%
vs 50-day avg +32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Software gross margin | 71% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SDGR
this stock
Schrodinger, Inc.
|
$2.16B | +61.6% | +23.3% | — | 14.9% |
|
VEEV
Veeva Systems Inc
|
$45.44B | +27.0% | +28.1% | 45.9 | 3.1% |
|
TEM
Tempus AI, Inc.
|
$15.34B | +21.9% | +83.4% | — | 15.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.20B | -29.7% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.02B | +70.2% | +28.2% | 33.8 | 5.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SDGR | -4.7% | +44.3% | +133.1% | -6.9% | +61.6% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -6.7% | +42.6% | +121.8% | -9.1% | +47.4% |